| 41/425 | US=12 / Urologia Rukstalis DB, Kenneson MA. Prostate cryoablation: successful therapy for clinically localized prostate cancer. In: Su LM. Prostate cancer. Philadelphia: Elsevier Saunders, 2010. p. 193-206. (Early Diagnosis and Treatment of Cancer Series) ISBN 978-1-4160-4575-5. |
| 42/425 | US=12 / Urologia Katz A. Alternative medicine for prostate cancer: diet, vitamins, minerals, and supplements. In: Su LM. Prostate cancer. Philadelphia: Elsevier Saunders, 2010. p. 207-28. (Early Diagnosis and Treatment of Cancer Series) ISBN 978-1-4160-4575-5. CANCER DE PROSTATA; MEDICINA ALTERNATIVA; DIETA; VITAMINAS; MINERAIS; SUPLEMENTACAO NUTRICIONAL; INGESTAO CALORICA; OBESIDADE; QUIMIOPREVENCAO |
| 43/425 | US=9 / Urologia Gleave ME, Cox ME, Wang Y. Cell biology of prostate cancer and molecular targts. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 1-24. ISBN 978-1-60327-831-7. RESISTENTE A CASTRACAO CANCER DE PROSTATA; RECEPTOR DE ANDROGENO; CLUSTERINA; HSP27; IGF-1 |
| 44/425 | US=12 / Urologia Levinson AW. Controversies in prostate cancer. In: Su LM. Prostate cancer. Philadelphia: Elsevier Saunders, 2010. p. 229-50. (Early Diagnosis and Treatment of Cancer Series) ISBN 978-1-4160-4575-5. CANCER DE PROSTATA; DIETA; FINASTERIDA; CANCER DE PROSTATA. TRATAMENTO; BRAQUITERAPIA; TERAPIA ABLATIVA |
| 45/425 | US=9 / Urologia Schally AV, Block NL. Luteinizing hormone-releasing hormone and its agonistic, antagonistic, and targeted cytotoxic analogs in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 27-39. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; SECRECAO DE LH; SECRECAO FSH; ESTEROIDES SEXUAIS; GONADOTROFINA; CASTRACAO QUIMICA; EFEITOS ANTICANCERIGENOS; CRESCIMENTO DO TUMOR; PROLIFERACAO CELULAR; RECEPTOR LHRH |
| 46/425 | US=9 / Urologia Heemers HV, Tindall DJ. Nuclear receptor coregulators: promising therapeutic targets for the treatment of prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 41-51. ISBN 978-1-60327-831-7. CANCER DE PROSTATA. TRATAMENTO; RECEPTOR DE ANDROGENO; ANDROGENO; COATIVADOR; COREPRESSOR; PROLIFERACAO CELULAR |
| 47/425 | US=9 / Urologia Prince DK, Hsing AW. Androgens and prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 53-9. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; ANDROGENOS; TESTOSTERONA; TERAPIA DE REPOSICAO |
| 48/425 | US=9 / Urologia Gelmann EP. Androgen receptor biology in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 61-70. ISBN 978-1-60327-831-7. ANDROGENO RECEPTOR DE BIOLOGIA; CANCER DE PROSTATA; RECEPTOR DE ANDROGENO; ANDROGENO; MUTACAO; COATIVADOR; BETA-CATENINA; P160 |
| 49/425 | US=9 / Urologia Shen HC, Taplin ME, Balk SP. Androgen receptor antagonists. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 71-81. ISBN 978-1-60327-831-7. ANTAGONISTAS DO RECEPTOR DE ANDROGENO; CANCER PROSTATA; ESTEROIDES; ESTEROIDE RECEPTOR; TESTOTERONA; DIIDROTESTOSTERONA; ANTAGONISTA; BICALUTAMIDA; FLUTAMIDA; NILUTAMIDA |
| 50/425 | US=9 / Urologia Culig Z. 5-Alpha reductase inhibitors in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 83-9. ISBN 978-1-60327-831-7. CANCER DE PROSTATA; 5-ALFA REDUTASE; DUTASTERIDE; FINASTERIDE; ISOENZIMA |
| 51/425 | US=9 / Urologia Friedlander TW, Ryan CJ. Adrenal androgen synthesis inhibitor therapies in castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 91-100. ISBN 978-1-60327-831-7. SINTESE DE ANDROGENOS ADRENAIS; TERAPIAS INIBIDOR NA CASTRACAO-RESISTENTE; CANCER DE PROSTATA; TERAPIA HORMONAL SECUNDARIA; ANDROGENIOS ADRENAIS; ANDROGENO-INDEPENDENTES CANCER DE PROSTATA; CANCER DE PROSTATA HORMONIO REFRATARIO; FASE I; FASE I DE ENSAIOS CLINICOS; FARMACOCINETICA |
| 52/425 | US=9 / Urologia Sharifi N. Androgen deprivation therapy. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 101-7. ISBN 978-1-60327-831-7. TERAPIA DE PRIVACAO DE ANDROGENO; TERAPIA DE PRIVACAO DE ANDROGENO; ANDROGENOS; CANCER DE PROSTATA; TESTOSTERONA |
| 53/425 | US=9 / Urologia Marques FZC, Reichardt JKV. Pharmacogenetics of the androgen metabolic pathway. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 109-21. ISBN 978-1-60327-831-7. FARMACOGENETICA; ANDROGENOS; DOENCA MULTIFATORIAL; CANCER DE PROSTATA; CANCER DE PROSTATA. TRATRAMENTO; CANCER DE PROSTATA. PREVENCAO; CANCER DE PROSTATA. FARMACOGENETICA |
| 54/425 | US=9 / Urologia Halterman P, Vogelzang NJ, Farabishahadel A, Goodman Jr OB. Mitoxantrone. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 125-31. ISBN 978-1-60327-831-7. MITOXANTRONA; DHAD; CANCER DE PROSTATA; CRPC; TERAPIA DE RESGATE |
| 55/425 | US=9 / Urologia Phillips CK, Petrylak DP. Docetaxel. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 133-46. ISBN 978-1-60327-831-7. DOCETAXEL; QUIMIOTERAPIA; SOBREVIVENCIA; RESISTENTE A CASTRACAO CANCER DE PROSTATA |
| 56/425 | US=9 / Urologia Rosenberg J. Beyond Docetaxel: emerging agents in the treatment of advanced prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 147-51. ISBN 978-1-60327-831-7. DOCETAXEL; CANCER DE PROSTATA AVANCADO; INIBICAO DE MTOR; NOVAS TERAPEUTICAS; DESACETILACAO DAS HISTONAS; HSP90; FATOR 1 DE CRESCIMENTO COM INSULINA |
| 57/425 | US=9 / Urologia Brick A, Niu J, Huang J, Oh WK. Platinum agents in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 153-61. ISBN 978-1-60327-831-7. AGENTES DE PLATINA NO CANCER DE PROSTATA; CARBOPLATINA; NEUROENDOCRINO; RESISTENTE A CASTRACAO; QUIMIOTERAPIA |
| 58/425 | US=9 / Urologia Sissung TM, Figg WD. Clinical pharmacology and pharmacogenetics of chemotherapy in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 163-77. ISBN 978-1-60327-831-7. FARMACOGENETICA DA QUIMIOTERAPIA. CANCER DE PROSTATA; FARMACOLOGIA CLINICA; DOCETAXEL; MITOXANTRONA; ESTRAMUSTINA; SATRAPLATIN; CANCER DE PROSTATA; FARMACOGENETICA; FARMACOLOGIA |
| 59/425 | US=9 / Urologia Fojo AT, Adelberg DE. Microtubule targeting agents. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 179-94. ISBN 978-1-60327-831-7. CITOESQUELETO; MICROTUBULOS; TUBULINA; QUIMIOTERAPIA; CANCER DE PROSTATA |
| 60/425 | US=9 / Urologia Chau CH, Figg WD. Principles of antiangiogenic therapy. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 197-205. ISBN 978-1-60327-831-7. TERAPIA ANTIANGIOGENICA; ANGIOGENESE; INTERRUPTOR ANGIOGENICO; INIBIDOR DA ANGIOGENESE; DENSIDADE MICROVASCULAR; ANTIANGIOGENICA TERAPIA |